Ultragenyx Pharmaceutical (RARE) Change in Cash (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Cash data on file, last reported at -$247.0 million in Q1 2026.

• Change in Cash for Q1 2026 came in at -$247.0 million, down 448.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.0 million (up 193.62% YoY), and the FY2025 annual result was $252.0 million, up 820.0% from the prior year.
• Change in Cash eased to -$247.0 million in Q1 2026 per RARE's latest filing, from $221.5 million in the prior quarter.
• Over five years, Change in Cash peaked at $367.9 million in Q2 2024 and troughed at -$330.0 million in Q3 2024.
• A 5-year average of -$7.1 million and a median of $6.5 million in 2022 frame the typical range for Change in Cash.
• On a YoY basis, Change in Cash climbed as much as 2179.24% in 2024 and fell as far as 1035.71% in 2024.
• A 5-year view of Change in Cash shows it stood at -$258.7 million in 2022, then soared by 154.11% to $140.0 million in 2023, then slumped by 82.72% to $24.2 million in 2024, then jumped by 815.69% to $221.5 million in 2025, then sank by 211.53% to -$247.0 million in 2026.
• Business Quant data shows RARE's Change in Cash at -$247.0 million in Q1 2026, $221.5 million in Q4 2025, and $26.1 million in Q3 2025.